Prognostic impact of prior LVEF in patients with heart failure with mildly reduced ejection fraction

射血分数 医学 内科学 心力衰竭 心脏病学 比例危险模型 临床终点 对数秩检验 临床试验
作者
Alexander Schmitt,Michael Behnes,Kathrin Weidner,Mohammad Abumayyaleh,Marielen Reinhardt,Noah Abel,Felix Lau,Jan Forner,Mohamed Ayoub,Kambis Mashayekhi,İbrahim Akın,Tobias Schupp
出处
期刊:Clinical Research in Cardiology [Springer Nature]
标识
DOI:10.1007/s00392-024-02443-0
摘要

Abstract Aims As there is limited evidence regarding the prognostic impact of prior left ventricular ejection fraction (LVEF) in patients with heart failure with mildly reduced ejection fraction (HFmrEF), this study investigates the prognostic impact of longitudinal changes in LVEF in patients with HFmrEF. Methods Consecutive patients with HFmrEF (i.e. LVEF 41–49% with signs and/or symptoms of HF) were included retrospectively in a monocentric registry from 2016 to 2022. Based on prior LVEF, patients were categorized into three groups: stable LVEF, improved LVEF, and deteriorated LVEF. The primary endpoint was 30-months all-cause mortality (median follow-up). Secondary endpoints included in-hospital and 12-months all-cause mortality, as well as HF-related rehospitalization at 12 and 30 months. Kaplan–Meier and multivariable Cox proportional regression analyses were applied for statistics. Results Six hundred eighty-nine patients with HFmrEF were included. Compared to their prior LVEF, 24%, 12%, and 64% had stable, improved, and deteriorated LVEF, respectively. None of the three LVEF groups was associated with all-cause mortality at 12 ( p ≥ 0.583) and 30 months (31% vs. 37% vs. 34%; log rank p ≥ 0.376). In addition, similar rates of 12- ( p ≥ 0.533) and 30-months HF-related rehospitalization (21% vs. 23% vs. 21%; log rank p ≥ 0.749) were observed. These findings were confirmed in multivariable regression analyses in the entire study cohort. Conclusion The transition from HFrEF and HFpEF towards HFmrEF is very common. However, prior LVEF was not associated with prognosis, likely due to the persistently high dynamic nature of LVEF in the follow-up period. Graphical Abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
stt发布了新的文献求助10
刚刚
刚刚
Ling完成签到,获得积分10
刚刚
TanFT完成签到,获得积分10
1秒前
笙歌自若发布了新的文献求助10
1秒前
1秒前
CipherSage应助积极的凌波采纳,获得10
2秒前
2秒前
烟花应助欣慰硬币采纳,获得10
2秒前
老大爷滴滴完成签到,获得积分10
2秒前
2秒前
2秒前
SciGPT应助LEMON采纳,获得10
3秒前
搜集达人应助叶飞荷采纳,获得10
3秒前
wxy完成签到,获得积分10
3秒前
4秒前
弄香完成签到,获得积分10
4秒前
gguc完成签到,获得积分10
4秒前
4秒前
无聊又夏完成签到,获得积分10
5秒前
今后应助木野狐采纳,获得10
5秒前
6秒前
小木木壮发布了新的文献求助10
6秒前
6秒前
6秒前
欢喜从霜发布了新的文献求助10
6秒前
7秒前
Ll发布了新的文献求助10
7秒前
茶艺如何发布了新的文献求助10
8秒前
落后秋柳发布了新的文献求助10
8秒前
科研通AI5应助大方嵩采纳,获得10
8秒前
9秒前
9秒前
海鸥海鸥发布了新的文献求助10
9秒前
南敏株完成签到,获得积分10
10秒前
稳重完成签到 ,获得积分10
11秒前
11秒前
11秒前
mi发布了新的文献求助10
11秒前
12秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762